Zynex (NASDAQ:ZYXI - Get Free Report) had its price objective decreased by research analysts at HC Wainwright from $17.00 to $15.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price objective indicates a potential upside of 114.29% from the stock's previous close.
Other research analysts have also recently issued reports about the stock. Royal Bank of Canada cut shares of Zynex from an "outperform" rating to a "sector perform" rating and reduced their price objective for the company from $11.00 to $5.50 in a report on Wednesday. LADENBURG THALM/SH SH cut shares of Zynex from a "buy" rating to a "neutral" rating in a report on Wednesday.
Get Our Latest Analysis on ZYXI
Zynex Trading Down 2.4 %
NASDAQ:ZYXI opened at $7.00 on Wednesday. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66. The stock has a market capitalization of $222.92 million, a price-to-earnings ratio of 46.67 and a beta of 0.81. The firm has a fifty day simple moving average of $7.72 and a two-hundred day simple moving average of $8.02. Zynex has a 12 month low of $4.36 and a 12 month high of $13.19.
Zynex (NASDAQ:ZYXI - Get Free Report) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.11). Zynex had a return on equity of 13.05% and a net margin of 2.49%. During the same quarter last year, the firm earned $0.04 earnings per share. Analysts expect that Zynex will post 0.2 EPS for the current fiscal year.
Insider Activity at Zynex
In related news, CFO Daniel J. Moorhead sold 10,000 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $7.15, for a total transaction of $71,500.00. Following the transaction, the chief financial officer now directly owns 10,050 shares of the company's stock, valued at $71,857.50. This trade represents a 49.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 30,000 shares of company stock valued at $227,100 over the last ninety days. Corporate insiders own 52.13% of the company's stock.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in ZYXI. Janney Montgomery Scott LLC lifted its position in shares of Zynex by 22.3% during the third quarter. Janney Montgomery Scott LLC now owns 144,439 shares of the company's stock valued at $1,179,000 after purchasing an additional 26,368 shares in the last quarter. GSA Capital Partners LLP lifted its position in shares of Zynex by 72.7% during the third quarter. GSA Capital Partners LLP now owns 79,930 shares of the company's stock valued at $652,000 after purchasing an additional 33,649 shares in the last quarter. Royce & Associates LP raised its position in Zynex by 9.2% in the third quarter. Royce & Associates LP now owns 257,291 shares of the company's stock worth $2,099,000 after acquiring an additional 21,781 shares during the period. Gladius Capital Management LP raised its position in Zynex by 53.4% in the third quarter. Gladius Capital Management LP now owns 5,002 shares of the company's stock worth $41,000 after acquiring an additional 1,742 shares during the period. Finally, Quest Partners LLC raised its position in Zynex by 131.3% in the third quarter. Quest Partners LLC now owns 29,898 shares of the company's stock worth $244,000 after acquiring an additional 16,972 shares during the period. 29.68% of the stock is owned by institutional investors.
About Zynex
(
Get Free Report)
Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zynex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zynex wasn't on the list.
While Zynex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
